From the source
- Alphabet's AI drug discovery company
Isomorphic Labs has raised $5 billion, its second billion-dollar round in six months, co-led by Greenoaks and Sequoia Capital.
- The company had already raised $2.1 billion back in May 2026, and the new money will go toward advancing its in-house platform IsoDDE and pushing its drug pipeline toward clinical trials.
- IsoDDE goes beyond AlphaFold 3, according to the company founded in 2021, and is meant to better predict drug binding and docking sites.
- Isomorphic Labs works with Novartis, Eli Lilly, and Johnson & Johnson but has no approved drug to show for it yet.
- The company is led by Demis Hassabis, who stepped down from day-to-day leadership of
Google Deepmind in August 2026 and now serves as Alphabet's Chief Scientist.
- Deepmind's original AlphaFold team was disbanded in July 2026, with many researchers moving to Isomorphic Labs or being reassigned, and nearly a quarter leaving Deepmind entirely.